Item no. |
HY-14689-10mg |
Manufacturer |
MedChem Express
|
CASRN |
190133-94-9 |
Amount |
10 mg |
Quantity options |
100 mg
10 mg
1 ea
25 mg
50 mg
5 mg
|
Category |
|
Type |
Inhibitors |
Specific against |
other |
Purity |
99.46 |
Formula |
C19H21Cl2NO |
Citations |
[1]Wu WL, et, al. Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists. J Med Chem. 2005 Feb 10;48(3):680-93. [2]Sharopov S, et al. Dopaminergic modulation of low-Mg²⁺-induced epileptiform activity in the intact hippocampus of the newborn mouse in vitro. J Neurosci Res. 2012 Oct;90(10):2020-33. [3]Satanove DJ, et al. Nicotine-induced enhancement of a sensory reinforcer in adult rats: antagonist pretreatment effects. Psychopharmacology (Berl). 2021 Feb;238(2):475-486. [4]R E Chipkin, et al. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity. J Pharmacol Exp Ther. 1988 Dec;247(3):1093-102. [5]E Acquas, et al. Local application of SCH 39166 reversibly and dose-dependently decreases acetylcholine release in the rat striatum. Eur J Pharmacol. 1999 Nov 3;383(3):275-9. |
Smiles |
OC1=C(Cl)C=C2C([C@]3([H])[C@@](CCC4=C3C=CC=C4)([H])N(C)CC2)=C1.[H]Cl |
ECLASS 10.1 |
32160490 |
ECLASS 11.0 |
32160490 |
UNSPSC |
12000000 |
Alias |
SCH 39166 (hydrochloride) |
Available |
|
Product Description |
Ecopipam (SCH 39166) hydrochloride is a potent, selective and orally active antagonist of dopamine D1/D5 receptor, with Kis of 1.2 nM and 2.0 nM, respectively. Ecopipam hydrochloride shows more than 40-flod selectivity over D2, D4, 5-HT, and α2a receptor (Ki=0.98, 5.52, 0.08, and 0.73 μM, respectively). Ecopipam hydrochloride can be used for the research of schizophrenia and obesity[1][3]. |
StorageTemperature |
4°C (Powder, sealed storage, away from moisture) |
Shipping |
Room Temperature |
Manufacturers Applications |
Metabolism-protein/nucleotide metabolism |
MolecularWeight |
350.28 |
Clinical Information |
Phase 3 |
Manufacturers Research Area |
Metabolic Disease; Neurological Disease |
Solubility |
DMSO : 100 mg/mL (ultrasonic) |
Target |
5-HT Receptor; Adrenergic Receptor; Dopamine Receptor |
Manufacturers Target |
5-HT Receptor; Adrenergic Receptor; Dopamine Receptor |
Isoform |
5-HT Receptor; D1 Receptor; D2 Receptor; D4 Receptor; D5 Receptor; α adrenergic receptor |
Manufacturers Pathway |
GPCR/G Protein; Neuronal Signaling |
Manufacturers Product type |
Reference compound |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.